Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma.

Autor:	Niemelä T; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Kankaanranta H; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland.; Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden., Vähätalo I; Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland., Loponen J; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland., Tuomisto LE; Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland., Niemelä O; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Department of Laboratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland., Hämäläinen M; The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland., Moilanen E; The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland., Ilmarinen P; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland.
Jazyk:	angličtina
Zdroj:	Journal of asthma and allergy [J Asthma Allergy] 2022 May 10; Vol. 15, pp. 579-593. Date of Electronic Publication: 2022 May 10 (Print Publication: 2022).
DOI:	10.2147/JAA.S356083
Abstrakt:	Background: Soluble urokinase plasminogen activator receptor (suPAR) has emerged as a novel biomarker for various inflammatory conditions and has been proposed to associate with the severity of asthma. However, the relationship between suPAR and clinical asthma features is poorly understood. Objective: To examine associations of serum suPAR levels with clinical characteristics of asthma and to define the phenotype with high suPAR levels in patients with adult-onset asthma. Methods: Serum suPAR levels were measured with ELISA from patients with adult-onset asthma participating in the 12-year follow-up visit in the Seinäjoki Adult Asthma Study. Results: In total, 201 patients were divided into quartiles according to suPAR values. High suPAR patients had more severe asthma symptoms and poorer asthma control. They also had higher levels of interleukin 8 (IL-8), interleukin 6 (IL-6), matrix metalloproteinase 9 (MMP-9), and blood neutrophil counts than those with low suPAR levels. The use of high-dose inhaled and oral corticosteroids was more common in patients with elevated suPAR. Such patients also had visited healthcare more frequently during the follow-up period, had more comorbidities, and were physically less active than those with low suPAR levels. The above-mentioned results remained similar after excluding the patients with co-existing COPD; only association to hospitalizations was lost. In multivariable binary regression analyses, the highest suPAR quartile was associated with higher cumulative dispensed oral corticosteroid use, more severe symptoms, and uncontrolled asthma. Conclusion: High suPAR levels occur in uncontrolled adult-onset asthma patients characterized by neutrophilic inflammation, high corticosteroid use, frequent healthcare visits, and multimorbidity with unhealthy lifestyle. This biomarker could be useful in determining asthma phenotypes and target new asthma treatments. Competing Interests: The authors declare no conflict of interest related to this study. Dr. Kankaanranta reports grants, personal fees and non-financial support from AstraZeneca, personal fees from Chiesi Pharma AB, GlaxoSmithKline, MSD, Novartis, Mundipharma, Sanofi, SanofiGenzyme, and personal fees and non-financial support from Boehringer-Ingelheim, and Orion Pharma, outside the submitted work. Dr. Vähätalo reports personal fees from Astra Zeneca, outside the submitted work. Dr. Loponen reports personal fees from Astra Zeneca and grants from Tampere Tuberculosis Foundation and Finnish Anti-Tuberculosis Association Foundation, outside the submitted work. Dr. Tuomisto reports non-financial support and personal fees from Chiesi, Boehringer-Ingelheim, personal fees from Astra Zeneca and GlaxoSmithKline, and non-financial support from TEVA, outside the submitted work. Eeva Moilanen reports grants from Tampere University Hospital (VTR grant) during the conduct of the study. Dr. Ilmarinen is an employee of and reports lecture fees from GlaxoSmithKline, reports grants and personal fees from Astra Zeneca, and personal fees from Mundipharma, GlaxoSmithKline, and Novartis, outside the submitted work. (© 2022 Niemelä et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu